Good Tysabri performance fails to raise analysts' hopes for Elan
This article was originally published in Scrip
Executive Summary
Elan's revenue continued its rapid growth in the third quarter, increasing by 53% to $270.1 million. Another strong performance by its multiple sclerosis and Crohn's disease treatment Tysabri (natalizumab), contributed $164.5 million (+159%) to Elan's total revenue. Tysabri's total in-market net sales increased by 154% to $237 million.